ANI Pharmaceuticals
ANIP
117 hedge funds and large institutions have $214M invested in ANI Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 42 reducing their positions, and 15 closing their positions.
41% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $784K
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
4% more capital invested
Capital invested by funds: $206M → $214M (+$8.18M)
1% more funds holding
Funds holding: 116 → 117 (+1)
0.31% more ownership
Funds ownership: 59.37% → 59.68% (+0.31%)
7% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 42
Top Buyers
Top Sellers
ANIP Hedge Fund Activity: Q4 2020 in Review
117 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2020, worth a combined $214M — up 4% from $206M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ANIP positions and 15 closed out — a net gain of 2 holders — while 39 added to existing stakes and 42 trimmed.
The largest buyer was First Wilshire Securities Management, opening a new position worth an estimated $4.6M. The largest seller was Global Alpha Capital Management, exiting entirely with an estimated $7.3M sold.
- 117 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2020, up from 116 in Q3 2020.
- Funds reported $214M of ANI Pharmaceuticals stock for Q4 2020, up 4% quarter-over-quarter.
- 17 funds opened new ANI Pharmaceuticals positions in Q4 2020 and 15 closed out, a net change of +2 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2020 was First Wilshire Securities Management, an estimated $4.6M added.
- The largest ANI Pharmaceuticals seller in Q4 2020 was Global Alpha Capital Management, an estimated $7.3M sold.
Based on aggregated 13F filings for Q4 2020.